Market Access News | pharmaphorum

News

FDA delays decision on Moderna’s RSV vaccine

Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US.

News

Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM

Three years after turning it down for being too expensive, NICE has backed the use of Pfizer’s Vyndaqel as a treatment for transthyretin amyloidosis with cardiomyopathy (A

News

NICE backs wider tumour profiling use in early breast cancer

Three tests that can be used to profile tumours in people with breast cancer and predict whether they will respond to chemotherapy have been cleared for wider use by the N

News

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a de

News

Price cut unlocks NHS use of sickle cell drug Oxbryta

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after a

News

MHRA ‘sandbox’ to pilot AI regulation will go live soon

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has said it will launch a pilot programme in the coming weeks to see how it can evolve the regulation o

FDA delays decision on Moderna’s RSV vaccine

Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM

NICE backs wider tumour profiling use in early breast cancer

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

Price cut unlocks NHS use of sickle cell drug Oxbryta

MHRA ‘sandbox’ to pilot AI regulation will go live soon

BridgeBio gains on phase 3 dwarfism data

How to meet your physicians where they are online

News

Editor's Picks